The University of Southampton
University of Southampton Institutional Repository

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). The regimens were compared with regard to effects on survival, response rates, toxicity, and quality of life.
Patients and Methods: Eligible patients had previously untreated stage IIIB or IV NSCLC suitable for cisplatin-based chemotherapy. Randomly assigned patients were to receive four cycles, each at 3-week intervals, of carboplatin area under the curve of 5 on day 1 plus gemcitabine 1,200 mg/m2 on days 1 and 8 (GCa) or mitomycin 6 mg/m2, ifosfamide 3g/m2, and cisplatin 50 mg/m2 on day 1 (MIC).
Results: Between February 1999 and August 2001, 422 patients (GCa, n = 212; MIC, n = 210) were randomly assigned in the United Kingdom. The majority of patients received the intended four cycles (GCa, 64%; MIC, 61%). There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008). Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%). Overall response rates were similar (42% for GCa v 41% for MIC; P = .84). More thrombocytopenia occurred with GCa (P = .03), but this was not associated with increased hospital admission or fatality. GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
Conclusion: In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.
1527-7755
142-153
Rudd, R.M.
687eae3b-9d24-4451-b785-c79b9de64b8b
Gower, N.H.
c51ba03a-a573-42b0-bbc0-1055b14b16f9
Spiro, S.G.
495ba4da-a54a-47f8-b0ba-23c9e44aaddd
Eisen, T.G.
34153a42-6116-49e4-ae4b-0afed805b391
Harper, P.G.
43921ac2-78de-4b35-89f7-37a84b91aea3
Littler, J.A.H.
bc28852b-deac-4f5a-b449-9f1d44757048
Hatton, M.
622cb0b3-b635-47b6-a621-99fec6fe4d24
Johnson, P.W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Martin, W.M.C.
40774619-fe0f-4a1d-97d0-7e90d1e01e3a
Rankin, E.M.
402be2da-87f0-443f-ac24-9702cbcd5166
James, L.E.
1c53699e-ad27-4ffc-a4c9-eb7d61cfad05
Gregory, W.M.
cea7c53e-3baa-43af-89f2-94d783c3596f
Qian, W.
4081a032-ee26-4c53-8a87-e9553ccda8fd
Lee, S.M.
64ed0393-1540-4ce3-b9ae-e06b882d2cee
Rudd, R.M.
687eae3b-9d24-4451-b785-c79b9de64b8b
Gower, N.H.
c51ba03a-a573-42b0-bbc0-1055b14b16f9
Spiro, S.G.
495ba4da-a54a-47f8-b0ba-23c9e44aaddd
Eisen, T.G.
34153a42-6116-49e4-ae4b-0afed805b391
Harper, P.G.
43921ac2-78de-4b35-89f7-37a84b91aea3
Littler, J.A.H.
bc28852b-deac-4f5a-b449-9f1d44757048
Hatton, M.
622cb0b3-b635-47b6-a621-99fec6fe4d24
Johnson, P.W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Martin, W.M.C.
40774619-fe0f-4a1d-97d0-7e90d1e01e3a
Rankin, E.M.
402be2da-87f0-443f-ac24-9702cbcd5166
James, L.E.
1c53699e-ad27-4ffc-a4c9-eb7d61cfad05
Gregory, W.M.
cea7c53e-3baa-43af-89f2-94d783c3596f
Qian, W.
4081a032-ee26-4c53-8a87-e9553ccda8fd
Lee, S.M.
64ed0393-1540-4ce3-b9ae-e06b882d2cee

Rudd, R.M., Gower, N.H., Spiro, S.G., Eisen, T.G., Harper, P.G., Littler, J.A.H., Hatton, M., Johnson, P.W.M., Martin, W.M.C., Rankin, E.M., James, L.E., Gregory, W.M., Qian, W. and Lee, S.M. (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. Journal of Clinical Oncology, 23 (1), 142-153. (doi:10.1200/JCO.2005.03.037).

Record type: Article

Abstract

Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). The regimens were compared with regard to effects on survival, response rates, toxicity, and quality of life.
Patients and Methods: Eligible patients had previously untreated stage IIIB or IV NSCLC suitable for cisplatin-based chemotherapy. Randomly assigned patients were to receive four cycles, each at 3-week intervals, of carboplatin area under the curve of 5 on day 1 plus gemcitabine 1,200 mg/m2 on days 1 and 8 (GCa) or mitomycin 6 mg/m2, ifosfamide 3g/m2, and cisplatin 50 mg/m2 on day 1 (MIC).
Results: Between February 1999 and August 2001, 422 patients (GCa, n = 212; MIC, n = 210) were randomly assigned in the United Kingdom. The majority of patients received the intended four cycles (GCa, 64%; MIC, 61%). There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008). Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%). Overall response rates were similar (42% for GCa v 41% for MIC; P = .84). More thrombocytopenia occurred with GCa (P = .03), but this was not associated with increased hospital admission or fatality. GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
Conclusion: In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.

Text
26584.pdf - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: 2005
Additional Information: Supported in part by the London Lung Cancer Group London, UK (registered charity No. 1074994), which received funding from Lilly Oncology to support this trial.

Identifiers

Local EPrints ID: 26584
URI: http://eprints.soton.ac.uk/id/eprint/26584
ISSN: 1527-7755
PURE UUID: ae4936d1-423f-4fb0-9c60-5d637fd93cce
ORCID for P.W.M. Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 20 Apr 2006
Last modified: 16 Mar 2024 02:59

Export record

Altmetrics

Contributors

Author: R.M. Rudd
Author: N.H. Gower
Author: S.G. Spiro
Author: T.G. Eisen
Author: P.G. Harper
Author: J.A.H. Littler
Author: M. Hatton
Author: P.W.M. Johnson ORCID iD
Author: W.M.C. Martin
Author: E.M. Rankin
Author: L.E. James
Author: W.M. Gregory
Author: W. Qian
Author: S.M. Lee

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×